Wegovy Pill Triggers Oral Obesity Drug Race as Eli Lilly Advances Orforglipron Toward Approval

The new oral version of semaglutide has reached high prescription numbers since its recent release. A data firm called IQVIA reported over 300,000 prescriptions by the end of February. This growth represents one of the fastest drug launches in medical history. Clinical tests showed that patients lost about 17 percent of their body weight.

This success comes at a vital time for the drug maker. The company once led the market with its injectable weight loss medications. However, it recently lost value due to intense competition and some research failures. Its market worth dropped as other pharmaceutical companies gained more ground.

One major competitor moved quickly to take advantage of this change. Its main product is now the second most popular medicine in the world. Recent data show this company leads in total obesity drug prescriptions by a large margin. Consequently, the value of the company recently passed the 1 trillion dollar mark.

The next stage of this competition involves developing new pills. One company expects a federal agency to approve its oral drug in April 2026. This new pill helped patients lose about 12.4 percent of their weight in studies. Notably, this drug does not have the strict eating rules required by other pills.

Current oral treatments require patients to take the medicine on an empty stomach. People must also wait 30 minutes before eating or drinking anything. Company leaders call this a small daily task for patients to follow. Nevertheless, a more flexible pill could be much easier for many people to use.

The recent product launch shows that the company has improved its manufacturing. It previously struggled with supply shortages when the injectable version first came out. The firm has since built more factories and improved how it sends drugs to patients. Therefore, staying ahead of the competition remains its most important goal.

Upcoming changes to patent laws will also create new challenges for these companies. Protections for the main ingredient in these drugs will expire very soon in several markets. Many other manufacturers have already applied to make cheaper generic versions. Analysts believe these new options could cut the price of the drugs by half.

Recent data suggest that these new pills mostly attract people who are starting treatment. These patients are usually not switching over from the weekly injections. Thus, the pills are growing the total market rather than taking away existing sales. Experts believe that unique features will decide which drugs succeed in the long run.

Industry experts are watching these trends to see how they impact future sales. Success depends on how well the drugs work and how easy they are to take. Companies are spending billions of dollars to build enough factories for the high demand. Accordingly, the medical world is entering a period of very fast change.

Doctors also point out that patients must stay on their treatment plans to see results. Long term health depends on having medicine that is both easy to find and affordable. Insurance rules will likely determine which of these pills becomes the most popular choice. Therefore, companies must prove that their drugs are worth the cost to health systems.